Published in Gene Therapy Weekly, November 8th, 1999
"Replication-deficient adenovirus vectors are efficient vehicles for delivering therapeutic genes into mammalian cells," wrote P.R. Clark and colleagues, University Arizona, Arizona Cancer Center. "However, the high doses required to produce effective gene transfer in vivo can also cause unwanted cellular toxicity. To improve replication-deficient adenovirus transgene expression while minimizing adverse reactions, we have tested polycationic compounds for their ability to enhance adenovirus adsorption."
...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (1999-11-08)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.